Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Author Correction: SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial.
Journal: Nature medicine
Published: June 29, 2026
A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients with Small Cell Lung Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 24, 2024
Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma.
Journal: Neuro-oncology advances
Published: February 23, 2023
First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 19, 2020
Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination.
Journal: Therapeutic advances in neurological disorders
Published: June 17, 2020
Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study.
Journal: Journal of neurology
Published: December 12, 2019
Immune Response to Seasonal Influenza Vaccine in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Long-term Daclizumab Beta: A Prospective, Open-Label, Single-Arm Study.
Journal: International journal of MS care
Published: June 13, 2017
Daclizumab, an IL-2 modulating antibody for treatment of multiple sclerosis.
Journal: Expert review of clinical pharmacology
Published: December 07, 2013
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.
Journal: Lancet (London, England)
Published: April 09, 2013
Showing 1-11 of 11
Last Updated: 09/26/2026